Physician profile
Vimali Paul
NPI 1700881448
$7,559.45
in general payments reported to CMS, 2019-2025
31 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $542 · 2021: $1,110 · 2022: $1,177 · 2023: $1,358 · 2024: $1,040 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $718.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,519.77 | 2019-2025 | |
| Allergan, INC. | $903.71 | 2019-2023 | |
| Amgen INC. | $416.43 | 2020-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $331.04 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $260.98 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.19 | 2019-2025 | Jardiance, Ofev |
| Amarin Pharma, INC. | $187.39 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $186.77 | 2019-2022 | |
| Insulet Corporation | $174.39 | 2020-2024 | Omnipod |
| Novo Nordisk INC | $171.81 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $162.54 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $150.77 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $127.04 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.88 | 2021-2022 | |
| Astellas Pharma US INC | $79.10 | 2025 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $75.06 | 2022-2025 | |
| Daiichi Sankyo INC. | $65.46 | 2021-2024 | Injectafer |
| Exact Sciences Corporation | $62.17 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $61.00 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Eisai INC. | $41.67 | 2020-2021 | |
| Revance Therapeutics, INC. | $40.58 | 2025 | Daxxify |
| Ironwood Pharmaceuticals, INC | $29.93 | 2020 | |
| Janssen Pharmaceuticals, INC | $26.91 | 2019 | |
| Almatica Pharma LLC | $25.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.41 | 2020 | |
| Optinose US, INC. | $23.78 | 2025 | |
| Sumitomo Pharma America, INC. | $22.75 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $22.14 | 2025 | |
| Corcept Therapeutics | $20.48 | 2025 | Korlym |
| Galderma Laboratories, L.P. | $14.01 | 2023 | |
| Esperion Therapeutics, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimali Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.